Withdrawal Of Rx Naloxone Nasal Spray Approval Supports US Forecast For OTC-Only Market
Executive Summary
FDA withdrawal of sNDA for Emergent’s Narcan 2-mg nasal spray bears out agency’s forecast that firms with approved NDAs for Rx naloxone products using a variety of delivery formats should prepare for an all-nonprescription market.